Login to Your Account

NewCo News

Rose Pharma Seeks Funding for Cell Mechanics Approach to DMD

By Trista Morrison

Thursday, January 6, 2011
With published data in hand and preclinical studies underway, Rose Pharmaceuticals is raising money to advance GsMTx4, a nontoxic peptide from spider venom intended to slow muscle degradation in Duchenne's muscular dystrophy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription